Antihypertensives and melanoma: An updated review

Williams, Natalie M.; Vincent, Louis; Rodriguez, Gregor A.; Nouri, Keyvan

doi:10.1111/pcmr.12918

Cited by 8 publications

(13 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Researchers have proposed several theories to interpret their therapeutic effects in various dermatoses [ 7 ]. In general, they may inhibit angiogenesis in dermatoses of vascular origin, such as rosacea [ 8 ], inhibit β-adrenergic receptors in melanocytes, and slow tumor growth in dermatoses of non-vascular origin, such as melanoma [ 9 ], and may also promote wound healing [ 10 ].…”

Section: Resultsmentioning

confidence: 99%

The Role of Systemic and Topical Beta-Blockers in Dermatology: A Systematic Review

Alhazmi

Basendwh

Aman

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Beta-blockers are proven to be safe and cost-effective agents in treating multiple dermatological conditions, which is why they are considered as an interesting and good alternative therapeutic agent by dermatologists. To our knowledge, there has been no comprehensive systematic review to date summarizing the role of both systemic and topical betablockers in dermatology. Methods: In this systematic review, we aim to review recent and relevant published literature in order to provide a comprehensive evidencebased summary to inform dermatologists. Results: An electronic-based literature search was carried out during October-December 2021 in the databases PubMed (MEDLINE), SCOPUS (EMBASE), and Cochrane Library. Furthermore, bibliographic sources were also reviewed for the selected articles. We followed The Preferred Reporting Items for Systematic Reviews and Meta-analyses 2020 (PRISMA) guidelines. We reviewed published literature about the role of beta-blockers in dermatology for the time period (January 2016 to December 2021). Conclusions: A total of 126 publications were retrieved from different databases, of which 59 studies were finally included in our review after excluding non-eligible literature in accordance with our inclusion and exclusion criteria. The included articles consisted of meta-analyses, systematic reviews, clinical trials, retrospective and prospective cohort studies, case-control studies, case series, and case reports. In general, data in reviewed literature showed that both systemic and topical beta-blockers were reliable and safe therapeutic options in treating different dermatoses. Their effect has been studied as a mono-therapy, also as an adjuvant therapy combined with other current disease-specific therapeutic modalities such as lasers, radiation, chemotherapy, corticosteroids, or other betablockers options. Local and systemic adverse effects were mainly minor and non-significant.

show abstract

Section: Resultsmentioning

confidence: 99%

The Role of Systemic and Topical Beta-Blockers in Dermatology: A Systematic Review

Alhazmi

Basendwh

Aman

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…The trend of increasing CM incidence world-wide evokes the question of whether there are additional risk factors other than UV radiation. An association between commonly used drugs and risk for CM has been reported [ 25 , 26 , 27 ]. Some medications have secondary immuno-modulating effects in mouse models and human cell lines, but the clinical impact has to be validated [ 28 , 29 , 30 , 31 ].…”

Section: Discussionmentioning

confidence: 99%

Trend Shifts in Age-Specific Incidence for In Situ and Invasive Cutaneous Melanoma in Sweden

Eriksson

Nielsen

Vassilaki

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: The incidence of invasive cutaneous melanoma (CM) is increasing in Sweden. The aim was to present age- and sex-specific trends of the age-standardised incidence and the average annual percentage change (AAPC) for in situ and invasive CM. Methods: Joinpoint regression models were used to analyse data from the Swedish Cancer Register and the Swedish Melanoma Registry 1997–2018 (N = 35,350 in situ CM; 59,932 CM). Results: The AAPC of CM for women was 4.5 (4.1–5.0; p < 0.001) for the period 1997–2018. For men, the APCC was 4.2 (3.0–5.4; p < 0.001), with a significantly higher annual percentage change (APC) for the period 2000–2018 (5.0; 4.6–5.4; p < 0.001) compared to 1997–1999. An increasing annual incidence of CM ≤ 0.6 mm and 0.7 mm Breslow tumour thickness was found for men with a significant incidence shift for the period 2006–2015, respectively. Similarly for women, with a significantly higher APC for CM ≤ 0.6 mm from 2005. The incidence of intermediate thick CM (2.1–4.0 mm) has not increased since 2011. The incidence of CM > 4.0 mm has been increasing among both sexes, with a significantly lower APC among women from 2005. Conclusions: The incidence of in situ and low-risk CM ≤ 1.0 mm in tumour thickness has been rising among both sexes since the 2000s.

show abstract

“…A possible explanation regarding these divergent results was suggested by the study of Wrobel and Le Gal which outlined the effect of non-cardioselective beta-blockers such as propranolol that can inhibit both β1 and β2 adrenoreceptors in comparison with cardioselective beta-blockers that act only on β1-adrenoreceptors. Propranolol is considered to have an important role in the inhibition of melanoma growth by modulating angiogenesis, tumor proliferation, and cell survival [ 92 ]. Studies have shown that propranolol induces a decrease in tumor development and angiogenesis, both in primary tumors and metastatic ones, and also reduces the myeloid cell infiltration of primary tumors [ 93 , 94 , 95 ].…”

Section: Neurotransmitters and Melanomamentioning

confidence: 99%

Neuroendocrine Factors in Melanoma Pathogenesis

Scheau

Drăghici

Ilie

et al. 2021

Cancers

View full text Add to dashboard Cite

Melanoma is one of the most aggressive skin cancers with a sharp rise in incidence in the last decades, especially in young people. Recognized as a significant public health issue, melanoma is studied with increasing interest as new discoveries in molecular signaling and receptor modulation unlock innovative treatment options. Stress exposure is recognized as an important component in the immune-inflammatory interplay that can alter the progression of melanoma by regulating the release of neuroendocrine factors. Various neurotransmitters, such as catecholamines, glutamate, serotonin, or cannabinoids have also been assessed in experimental studies for their involvement in the biology of melanoma. Alpha-MSH and other neurohormones, as well as neuropeptides including substance P, CGRP, enkephalin, beta-endorphin, and even cellular and molecular agents (mast cells and nitric oxide, respectively), have all been implicated as potential factors in the development, growth, invasion, and dissemination of melanoma in a variety of in vitro and in vivo studies. In this review, we provide an overview of current evidence regarding the intricate effects of neuroendocrine factors in melanoma, including data reported in recent clinical trials, exploring the mechanisms involved, signaling pathways, and the recorded range of effects.

show abstract

Antihypertensives and melanoma: An updated review

Cited by 8 publications

References 54 publications

The Role of Systemic and Topical Beta-Blockers in Dermatology: A Systematic Review

The Role of Systemic and Topical Beta-Blockers in Dermatology: A Systematic Review

Trend Shifts in Age-Specific Incidence for In Situ and Invasive Cutaneous Melanoma in Sweden

Neuroendocrine Factors in Melanoma Pathogenesis

Contact Info

Product

Resources

About